Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R., Hoimes, Christopher J., George, Daniel J., Armstrong, Andrew J., Zhang, Tian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://ncbi.nlm.nih.gov/pubmed/33115529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00978-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller